share_log

3SBio Inc. (HKG:1530) Interim Results: Here's What Analysts Are Forecasting For This Year

3SBio Inc. (HKG:1530) Interim Results: Here's What Analysts Are Forecasting For This Year

三生製藥股份有限公司(HKG:1530)中期業績:這一年分析師們做出了怎樣的預測
Simply Wall St ·  08/24 20:15

It's been a mediocre week for 3SBio Inc. (HKG:1530) shareholders, with the stock dropping 12% to HK$5.73 in the week since its latest half-year results. 3SBio reported CN¥4.4b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of CN¥0.45 beat expectations, being 2.3% higher than what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

這對3SBio股東來說是一個平庸的一週,股票在最新半年度業績公佈後的一週下跌了12%,至5.73港元。3SBio報告了44億人民幣的營業收入,與分析師預測基本一致,儘管每股收益(EPS)爲0.45港元,超過了預期,比分析師預期高2.3%。分析師通常會在每次業績發佈後更新他們的預測,我們可以從他們的預測中判斷他們對公司的觀點是否發生了變化,或者是否有任何新的問題需要注意。我們已經收集到了最新的法定預測,以了解分析師是否在根據這些業績更新了他們的盈利模型。

1724544949901
SEHK:1530 Earnings and Revenue Growth August 25th 2024
8月25日2024年香港交易所股票代碼爲1530的公司盈利和營收增長

Taking into account the latest results, the consensus forecast from 3SBio's eleven analysts is for revenues of CN¥8.81b in 2024. This reflects a credible 4.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to expand 10% to CN¥0.78. In the lead-up to this report, the analysts had been modelling revenues of CN¥8.75b and earnings per share (EPS) of CN¥0.77 in 2024. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

考慮到最新的業績,3SBio的11位分析師的共識預測是2024年營業收入爲881億元人民幣。這相對於過去12個月的數據,反映出了4.6%的可靠增長。預計法定每股收益將擴大10%,達到0.78元人民幣。在此報告之前,分析師的盈收預測是2024年營收爲875億元人民幣,每股收益爲0.77元人民幣。所以明顯可以看出,儘管分析師已經更新了他們的預測,但對業務的預期並沒有發生重大變化。

The analysts reconfirmed their price target of HK$8.06, showing that the business is executing well and in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values 3SBio at HK$10.03 per share, while the most bearish prices it at HK$6.22. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

分析師重申了每股目標價港元8.06元的股票價格,表明公司在執行方面表現良好並與預期一致。專注於單一目標價可能不明智,因爲共識目標實際上是分析師目標價的平均值。因此,一些投資者喜歡看一下預估範圍,以了解對公司的估值是否有任何不同意見。目前,最看好的分析師將3SBio估值爲每股10.03港元,而最看淡的分析師將其估值爲每股6.22港元。如你所見,分析師對該股未來的看法並不完全一致,但預估範圍仍然相對較窄,這可能表明結果並非完全不可預測。

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We can infer from the latest estimates that forecasts expect a continuation of 3SBio'shistorical trends, as the 9.4% annualised revenue growth to the end of 2024 is roughly in line with the 10% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 25% per year. So it's pretty clear that 3SBio is expected to grow slower than similar companies in the same industry.

我們可以從更大的角度來看待這些預測,比如與過去業績的對比,以及相對於行業其他公司預測的看好程度。從最新預測中我們可以推斷出,預計3SBio的歷史趨勢將得到延續,到2024年底的年化收入增長率9.4%大致與過去五年的10%年度增長率相符。相比之下,我們的數據顯示,同行業其他有分析師覆蓋的公司預計每年收入增長25%。所以很明顯,3SBio預計增長速度將比同行業的其他公司慢。

The Bottom Line

最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that 3SBio's revenue is expected to perform worse than the wider industry. The consensus price target held steady at HK$8.06, with the latest estimates not enough to have an impact on their price targets.

最重要的一點是,市場情緒沒有發生重大變化,分析師們重申該公司的業績與之前的每股收益預測一致。幸運的是,分析師們也重申了他們對該公司營業收入的預測,表明該公司的表現與預期相符。儘管我們的數據確實顯示,3SBio的營業收入預計表現將比整個行業差。市場一致看好的目標價仍然保持在8.06港幣,最新的預測對其目標價沒有產生影響。

With that in mind, we wouldn't be too quick to come to a conclusion on 3SBio. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple 3SBio analysts - going out to 2026, and you can see them free on our platform here.

在這種情況下,我們不應該過於草率地得出關於3SBio的結論。長期的盈利能力比明年的利潤更重要。我們有從多個3SBio分析師那裏得到的截至2026年的預測,您可以在我們的平台上免費查看這些預測。

However, before you get too enthused, we've discovered 1 warning sign for 3SBio that you should be aware of.

然而,在你過於興奮之前,我們發現3SBio存在一個警示信號,你需要知道。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論